Equity Overview
Price & Market Data
Price: $0.43
Daily Change: $0.00 / 0.00%
Daily Range: $0.35 - $0.464
Market Cap: $3,641,219
Daily Volume: 92,539
Performance Metrics
1 Week: 24.49%
1 Month: 6.42%
3 Months: -23.58%
6 Months: -47.37%
1 Year: -55.26%
YTD: -23.58%
Details
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.